Moreover, the cancer patients with higher expression of SDCBP had poorer long-term overall survival rates in many other types of cancers including breast cancer (BRCA, P = 0.0083), glioblastoma (GBM, P = 0.0214), kidney renal papillary cell carcinoma (KIRP, P = 0.0104), low grade glioma (LGG, P < 0.0001), lung adenocarcinoma (LUAD, P = 0.0085), lung squamous cell carcinoma (LUSC, P = 0.0004), sarcoma (SARC, P = 0.0223), prostate adenocarcinoma (PAAD, P = 0.0130), thyroid carcinoma (THCA, P = 0.0021) and uveal melanoma (UVM, P = 0.0003) (Figure 3). This evidence concerns the gene SDCBP and prostate adenocarcinoma.